Literature DB >> 11357997

A case of chromomycosis treated by a combination of cryotherapy, shaving, oral 5-fluorocytosine, and oral amphotericin B.

J Poirriez1, F Breuillard, N Francois, J Fruit, B Sendid, S Gross, E Dei-Cas.   

Abstract

A case of chromomycosis from Comoro Islands was first treated without success with high doses of oral amphotericin B (3 g per day). Treatment with itraconazole (400 mg per day) was also unsuccessful. Then, in vitro tests were done to study the susceptibility of this Fonsecaea pedrosoi strain to antifungal drugs. It was resistant to itraconazole, sensitive to 5-fluorocytosine, and the combination of 5-fluorocytosine with amphotericin B was synergistic. The patient was then treated with this last combination of drugs, which seemed to be effective. The patient stopped this treatment after six months, and relapse occurred two years later. The best therapeutic strategy in cases of chromomycosis seems to be a combination of two drugs chosen according to the results of prior antifungal susceptibility testing.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11357997     DOI: 10.4269/ajtmh.2000.63.61

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  5 in total

1.  Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi.

Authors:  Enrique Calvo; F Javier Pastor; Emilio Mayayo; Pilar Hernández; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 2.  Chromoblastomycosis as an endemic disease in temperate Europe: first confirmed case and review of the literature.

Authors:  M Pindycka-Piaszczyńska; P Krzyściak; M Piaszczyński; S Cieślik; K Januszewski; G Izdebska-Straszak; J Jarząb; S de Hoog; T Jagielski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-19       Impact factor: 3.267

3.  New possibilities for chromoblastomycosis and phaeohyphomycosis treatment: identification of two compounds from the MMV Pathogen Box® that present synergism with itraconazole.

Authors:  Rowena Alves Coelho; Gabriela Machado Alves; Maria Helena Galdino Figueiredo-Carvalho; Fernando Almeida-Silva; Gabriela Rodrigues de Souza; Maria Cristina da Silva Lourenço; Fábio Brito-Santos; Ana Claudia Fernandes Amaral; Rodrigo Almeida-Paes
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-09-12       Impact factor: 2.747

4.  Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence.

Authors:  Vanila F Palmeira; Lucimar F Kneipp; Sonia Rozental; Celuta S Alviano; André L S Santos
Journal:  PLoS One       Date:  2008-10-13       Impact factor: 3.240

5.  Molecular identification and antifungal susceptibility profiles of clinical strains of Fonsecaea spp. isolated from patients with chromoblastomycosis in Rio de Janeiro, Brazil.

Authors:  Rowena Alves Coelho; Fábio Brito-Santos; Maria Helena Galdino Figueiredo-Carvalho; Juliana Vitoria Dos Santos Silva; Maria Clara Gutierrez-Galhardo; Antonio Carlos Francesconi do Valle; Rosely Maria Zancopé-Oliveira; Luciana Trilles; Wieland Meyer; Dayvison Francis Saraiva Freitas; Rodrigo Almeida-Paes
Journal:  PLoS Negl Trop Dis       Date:  2018-07-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.